CN1713900A - 去甲肾上腺素再摄取抑制剂在治疗认知障碍中的应用 - Google Patents

去甲肾上腺素再摄取抑制剂在治疗认知障碍中的应用 Download PDF

Info

Publication number
CN1713900A
CN1713900A CNA028247264A CN02824726A CN1713900A CN 1713900 A CN1713900 A CN 1713900A CN A028247264 A CNA028247264 A CN A028247264A CN 02824726 A CN02824726 A CN 02824726A CN 1713900 A CN1713900 A CN 1713900A
Authority
CN
China
Prior art keywords
treatment
application
tomoxetine
cognitive disorder
chemical compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028247264A
Other languages
English (en)
Chinese (zh)
Inventor
F·P·拜马斯特
D·R·格莱尔特
D·L·麦金兹
C·R·杨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN1713900A publication Critical patent/CN1713900A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CNA028247264A 2001-12-11 2002-11-27 去甲肾上腺素再摄取抑制剂在治疗认知障碍中的应用 Pending CN1713900A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33917401P 2001-12-11 2001-12-11
US60/339,174 2001-12-11

Publications (1)

Publication Number Publication Date
CN1713900A true CN1713900A (zh) 2005-12-28

Family

ID=23327833

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028247264A Pending CN1713900A (zh) 2001-12-11 2002-11-27 去甲肾上腺素再摄取抑制剂在治疗认知障碍中的应用

Country Status (26)

Country Link
US (1) US20050009925A1 (https=)
EP (1) EP1458368B1 (https=)
JP (1) JP2005517647A (https=)
KR (1) KR20040066895A (https=)
CN (1) CN1713900A (https=)
AU (1) AU2002352625A1 (https=)
BR (1) BR0213581A (https=)
CA (1) CA2467802A1 (https=)
CO (1) CO5590907A2 (https=)
CZ (1) CZ2004709A3 (https=)
DE (1) DE60223718T2 (https=)
EA (1) EA200400793A1 (https=)
EC (1) ECSP045145A (https=)
ES (1) ES2295435T3 (https=)
HR (1) HRPK20040528B3 (https=)
HU (1) HUP0402619A3 (https=)
IL (1) IL161989A0 (https=)
MX (1) MXPA04005716A (https=)
MY (1) MY136367A (https=)
NO (1) NO20042904L (https=)
NZ (1) NZ532065A (https=)
PL (1) PL369311A1 (https=)
SK (1) SK2442004A3 (https=)
TW (1) TW200300672A (https=)
WO (1) WO2003049724A1 (https=)
ZA (1) ZA200404274B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050049476A (ko) * 2002-08-14 2005-05-25 파마시아 앤드 업존 캄파니 엘엘씨 홍조를 치료하기 위한 레복세틴의 용도
ATE526954T1 (de) * 2003-07-28 2011-10-15 Leslie Joe Dunaway Atomoxetin zur behandlung von allergischer rhinitis und asthma
CA2530014A1 (en) * 2003-08-27 2005-03-10 Eli Lilly And Company Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors
KR20060121178A (ko) * 2003-12-12 2006-11-28 일라이 릴리 앤드 캄파니 일과성 전신 열감, 충동 조절 장애 및 일반적인 의학상태로 인한 인격 변화 치료용 선택적 노르에피네프린재흡수 억제제
JP4185154B2 (ja) * 2004-04-30 2008-11-26 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 中枢神経系障害治療用の置換モルホリン化合物
US7439399B2 (en) * 2004-06-28 2008-10-21 Teva Pharmaceutical Fine Chemicals Processes for the preparation of atomoxetine hydrochloride
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
US20100317731A1 (en) * 2009-06-12 2010-12-16 Shaya Elias K Hyperhidrosis treatment
TW201107485A (en) * 2009-07-31 2011-03-01 Univ Nat Taiwan Treating negative symptoms of schizophrenia associated with defective neuregulin 1 (NRG1)
EP2764863B1 (en) * 2011-10-03 2020-03-11 National Center for Geriatrics and Gerontology Tau aggregation inhibitor
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
EP2962687B1 (en) 2013-04-02 2019-06-05 The Doshisha Tau aggregation inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5658590A (en) * 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
DE60022692T2 (de) * 1999-07-01 2006-06-22 Pharmacia & Upjohn Co. Llc, Kalamazoo (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
WO2001027068A1 (en) * 1999-10-13 2001-04-19 Pfizer Products Inc. Biaryl ether derivatives useful as monoamine reuptake inhibitors
CA2431041A1 (en) * 2001-01-02 2002-07-11 Pharmacia & Upjohn Company New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
WO2002053104A2 (en) * 2001-01-02 2002-07-11 Sention, Inc. Use of catecholamine reuptake inhibitors to enhance memory

Also Published As

Publication number Publication date
CA2467802A1 (en) 2003-06-19
ECSP045145A (es) 2004-07-23
EP1458368A1 (en) 2004-09-22
TW200300672A (en) 2003-06-16
HUP0402619A3 (en) 2008-04-28
US20050009925A1 (en) 2005-01-13
NO20042904L (no) 2004-09-07
HUP0402619A2 (hu) 2005-03-29
BR0213581A (pt) 2004-08-24
EA200400793A1 (ru) 2004-10-28
IL161989A0 (en) 2005-11-20
ZA200404274B (en) 2005-09-13
DE60223718T2 (de) 2008-10-30
PL369311A1 (en) 2005-04-18
NZ532065A (en) 2007-03-30
MXPA04005716A (es) 2004-12-06
KR20040066895A (ko) 2004-07-27
ES2295435T3 (es) 2008-04-16
DE60223718D1 (de) 2008-01-03
JP2005517647A (ja) 2005-06-16
HRPK20040528B3 (en) 2006-03-31
CZ2004709A3 (cs) 2004-10-13
CO5590907A2 (es) 2005-12-30
EP1458368B1 (en) 2007-11-21
HRP20040528A2 (en) 2004-10-31
WO2003049724A1 (en) 2003-06-19
AU2002352625A1 (en) 2003-06-23
SK2442004A3 (en) 2004-12-01
MY136367A (en) 2008-09-30

Similar Documents

Publication Publication Date Title
DE60200492T2 (de) Kombination eines Inhibitoren der Serotoninwiederaufnahme und eines atypischen Antipsychotikums zur Behandlung von Depression, Zwangsneurosen und Psychosen
US10004731B2 (en) Flibanserin for the treatment of urinary incontinence and related diseases
RU2336879C2 (ru) Применение n-десметилклозапина для лечения нейропсихиатрических заболеваний у людей
CN1713900A (zh) 去甲肾上腺素再摄取抑制剂在治疗认知障碍中的应用
US9808455B2 (en) Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
CA2989319C (en) Pharmaceutical compositions for anesthesiological applications
US20050233010A1 (en) Lithium combinations, and uses related thereto
CN1311681A (zh) 顽固性抑郁治疗的联合疗法
US6960577B2 (en) Combination therapy for treatment of refractory depression
KR20020083138A (ko) 우울증의 치료 또는 인지 기능 감퇴의 예방 방법 및 키트
CN1252722A (zh) 脱羰乙氧氯雷他定在治疗尿失禁、晕动病和眩晕药剂的制备中的应用
JP2008525414A (ja) 精神病性障害を治療するためのサブコメリンと神経遮断薬との組み合わせ
US20240415848A1 (en) Pharmaceutical compositions and methods for anesthesiological applications
AU2007312209A1 (en) Composition comprising an NK-1 receptor antagonist and an SSRI for the treatment of tinnitus and hearing loss
US20200155568A1 (en) Pharmaceutical compositions and methods for anesthesiological applications
US20110065749A1 (en) Method and pharmaceutical composition for treatment of mental disorders
HK40113104A (en) Pharmaceutical compositions for anesthesiological applications
Post-MI IV. MEDICAL CAUSES OF DEPRESSION
HK1253720B (en) Pharmaceutical compositions for anesthesiological applications comprising benzodiazepine and ketamine
HK1063744A (en) Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20051228